AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2240539 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fentanyl
Number of subjects: 160
Study 2240539 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular placebo
Number of subjects: 160
Study 365312 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 5-fluorouracil (5-FU)
Number of subjects: 316
Study 365312 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous 5-fluorouracil (5-FU)
Number of subjects: 316
Study 365312 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Methyl CCNU
Number of subjects: 316
Study 365312 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) and 6-thioguanine
Number of subjects: 316
Study 365312 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide and 5-fluorouracil (5-FU)
Number of subjects: 316
Study 365312 — intervention group
Group type: COMPARATOR
Intervention: Crossover or previously treated patients
Number of subjects: 316
Study 365312 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU)
Number of subjects: 316
Study 365312 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl CCNU
Number of subjects: 316
Study 31566030 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg once daily for 5 days
Number of subjects: 12
Study 31566030 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 20 mg once daily for 5 days
Number of subjects: 12
Study 31566030 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 15 mg once daily for 5 days
Number of subjects: 12
Study 31566030 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg once daily for 5 days
Number of subjects: 12
Study 30879775 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavit G (3M ESPE)
Number of subjects: 120
Study 30879775 — intervention group
Group type: EXPERIMENTAL
Intervention: Coltosol F (Coltène/Whaledent AG)
Number of subjects: 120
Study 30879775 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate Restorative Material (Dentsply Sirona)
Number of subjects: 120
Study 30879775 — intervention group
Group type: EXPERIMENTAL
Intervention: DiaTemp (DiaDent Europe BV)
Number of subjects: 120
Study 30879775 — intervention group
Group type: COMPARATOR
Intervention: Negative control group (intact teeth)
Number of subjects: 120
Study 30879775 — intervention group
Group type: COMPARATOR
Intervention: Positive control group (no temporary filling material)
Number of subjects: 120
Study 28244907 — intervention group
Group type: COMPARATOR
Intervention: Intravenous tranexamic acid (1 g bolus)
Number of subjects: 83
Study 28244907 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tranexamic acid (1.95 g orally 2 hours preoperatively)
Number of subjects: 83
Study 28244907 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 83
Study 25823907 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week buprenorphine taper
Number of subjects: 28
Study 25823907 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-week buprenorphine taper
Number of subjects: 28
Study 25823907 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week buprenorphine taper
Number of subjects: 28
Study 25823907 — intervention group
Group type: EXPERIMENTAL
Intervention: Expected Withdrawal Severity (baseline rating)
Number of subjects: 28
Study 23578508 — intervention group
Group type: EXPERIMENTAL
Intervention: Degenerative aortic valves
Number of subjects: 22
Study 23578508 — intervention group
Group type: COMPARATOR
Intervention: Normal aortic valves
Number of subjects: 22
Study 21323599 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-normal target TSH (0.4-2.0 mIU/L)
Number of subjects: 42
Study 21323599 — intervention group
Group type: COMPARATOR
Intervention: High-normal target TSH (2.0-4.0 mIU/L)
Number of subjects: 42
Study 19337757 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (EX)
Number of subjects: 111
Study 19337757 — intervention group
Group type: COMPARATOR
Intervention: Posterolateral fusion (PLF)
Number of subjects: 111
Study 19337757 — intervention group
Group type: COMPARATOR
Intervention: Laminectomy
Number of subjects: 111
Study 19337757 — intervention group
Group type: COMPARATOR
Intervention: Patients without ASD
Number of subjects: 111
Study 17934662 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride 4 mg (Amaryl)
Number of subjects: 26
Study 15525713 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal injection of trivalent inactivated influenza vaccine (6 mug of hemagglutinin per antigen)
Number of subjects: 119
Study 15525713 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular injection of standard dose of trivalent inactivated influenza vaccine (15 mug of hemagglutinin per antigen)
Number of subjects: 119
Study 15525713 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular injection (control)
Number of subjects: 119
Study 15525713 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal injection
Number of subjects: 119
Study 11266374 — intervention group
Group type: EXPERIMENTAL
Intervention: LCT (long-chain triglycerides)
Number of subjects: 15
Study 11266374 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT (medium-chain triglycerides)
Number of subjects: 15
Study 11266374 — intervention group
Group type: EXPERIMENTAL
Intervention: LCT with THL (tetrahydrolipstatin)
Number of subjects: 15
Study 11266374 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT with THL
Number of subjects: 15
Study 11266374 — intervention group
Group type: COMPARATOR
Intervention: SPE (sucrose polyester)
Number of subjects: 15
Study 11266374 — intervention group
Group type: EXPERIMENTAL
Intervention: LCT
Number of subjects: 15
Study 11266374 — intervention group
Group type: EXPERIMENTAL
Intervention: LCT with THL
Number of subjects: 15
Study 11266374 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT
Number of subjects: 15
Study 11266374 — intervention group
Group type: COMPARATOR
Intervention: SPE
Number of subjects: 15
Study 11266374 — intervention group
Group type: EXPERIMENTAL
Intervention: THL or SPE
Number of subjects: 15
Study 9058868 — intervention group
Group type: EXPERIMENTAL
Intervention: VVIR 110
Number of subjects: 18
Study 7574735 — intervention group
Group type: EXPERIMENTAL
Intervention: Plachitin (300 mg, 100 mg as CDDP) - Group A
Number of subjects: 11
Study 7574735 — intervention group
Group type: EXPERIMENTAL
Intervention: Plachitin particles (300 mg) - Group B
Number of subjects: 11
Study 7574735 — intervention group
Group type: COMPARATOR
Intervention: CDDP (100 mg) - Group C
Number of subjects: 11
Study 2114208 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied cromolyn solution
Number of subjects: 0
Study 2114208 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 638545 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran 70
Number of subjects: 305
Study 638545 — intervention group
Group type: COMPARATOR
Intervention: Pneumatic calf compression
Number of subjects: 305
Study 638545 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran 70 and pneumatic calf compression (combined)
Number of subjects: 305
Study 638545 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups (including control)
Number of subjects: 305
Study 31602695 — intervention group
Group type: EXPERIMENTAL
Intervention: Crocus sativus capsules (30 mg daily, 15 mg twice/day)
Number of subjects: 73
Study 31602695 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules (twice/day)
Number of subjects: 73
Study 31602695 — intervention group
Group type: EXPERIMENTAL
Intervention: Crocus sativus capsules
Number of subjects: 73
Study 30763425 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy (HRT) 70 Gy in 28 fractions over 5.6 weeks
Number of subjects: 962
Study 30763425 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy (CRT) 73.8 Gy in 41 fractions over 8.2 weeks
Number of subjects: 962
Study 30763425 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy (HRT)
Number of subjects: 962
Study 30763425 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy (CRT)
Number of subjects: 962
Study 28156154 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin timing intervention (injected or infused 30 minutes before the meal to 15 minutes after the meal)
Number of subjects: 40
Study 28156154 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard insulin timing)
Number of subjects: 40
Study 28156154 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin timing intervention (for volunteers with baseline A1C in the upper half)
Number of subjects: 40
Study 28156154 — intervention group
Group type: COMPARATOR
Intervention: Control group (for volunteers with baseline A1C in the upper half)
Number of subjects: 40
Study 24731892 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil
Number of subjects: 150
Study 24731892 — intervention group
Group type: EXPERIMENTAL
Intervention: Saj(®) cream
Number of subjects: 150
Study 24731892 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 150
Study 22677689 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-segment osteotomy (3SO)
Number of subjects: 98
Study 22677689 — intervention group
Group type: COMPARATOR
Intervention: 2-segment osteotomy (2SO)
Number of subjects: 98
Study 20192896 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium thiosulfate (STS) infusion
Number of subjects: 32
Study 20192896 — intervention group
Group type: COMPARATOR
Intervention: No sodium thiosulfate (STS) infusion (Control)
Number of subjects: 32
Study 18462572 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulk-forming laxatives
Number of subjects: 19
Study 18462572 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant laxatives
Number of subjects: 19
Study 18462572 — intervention group
Group type: EXPERIMENTAL
Intervention: Osmotic laxatives
Number of subjects: 19
Study 18462572 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of laxatives
Number of subjects: 19
Study 18462572 — intervention group
Group type: EXPERIMENTAL
Intervention: EuroQoL 5 Dimensions
Number of subjects: 19
Study 18462572 — intervention group
Group type: EXPERIMENTAL
Intervention: Reported number of bowel movements per week
Number of subjects: 19
Study 18462572 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence/absence of the other Rome II criteria for constipation
Number of subjects: 19
Study 18462572 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse effects of treatment
Number of subjects: 19
Study 18462572 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse rates
Number of subjects: 19
Study 15854466 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial neural network model using serum protein fingerprint pattern
Number of subjects: 106
Study 12939313 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenomedullin (12.8 pmol/(kg. min))
Number of subjects: 8
Study 12939313 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenomedullin co-infused with N(G)‐monomethyl‐L‐arginine (3 mg/kg bolus and 30 micro g/(kg. min) continuous intravenous infusion)
Number of subjects: 8
Study 12939313 — intervention group
Group type: COMPARATOR
Intervention: Adrenomedullin
Number of subjects: 8
Study 10898265 — intervention group
Group type: EXPERIMENTAL
Intervention: Low resistance circuit weight training (CWT)
Number of subjects: 90
Study 10898265 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (END)
Number of subjects: 90
Study 10898265 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 90
Study 7727267 — intervention group
Group type: EXPERIMENTAL
Intervention: Workload and Student Misbehaviour
Number of subjects: 710
Study 7727267 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploratory factor analysis on Sample 1 (N = 335)
Number of subjects: 710
Study 7727267 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirmatory factor analysis on Sample 2 (N = 375)
Number of subjects: 710
Study 7727267 — intervention group
Group type: EXPERIMENTAL
Intervention: Structural modelling of causal relationships
Number of subjects: 710
Study 7727267 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple regression model
Number of subjects: 710
Study 1689245 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric coated microspheres (ECM)
Number of subjects: 20
Study 6997374 — intervention group
Group type: EXPERIMENTAL
Intervention: Subunit adsorbed chemical influenza vaccine (ACI) administered subcutaneously by needleless and syringe methods
Number of subjects: 0
Study 6997374 — intervention group
Group type: EXPERIMENTAL
Intervention: Revaccination with ACI vaccine
Number of subjects: 0
Study 6997374 — intervention group
Group type: COMPARATOR
Intervention: ACI vaccine, 'Vaxgrip', and 'Mutagripe'
Number of subjects: 0
Study 31923137 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention to increase STI screening and reduce sexual risk-taking behaviors
Number of subjects: 193
Study 31923137 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported history of STI among women
Number of subjects: 193
Study 31923137 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported history of STI among men
Number of subjects: 193
Study 30037208 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1 g IV before induction, followed by 1 g IV infusion at 8-hour intervals for 48 hours)
Number of subjects: 132
Study 30037208 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 132
Study 30037208 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 132
Study 28330455 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergames on Windows Kinect® (EG)
Number of subjects: 54
Study 28330455 — intervention group
Group type: COMPARATOR
Intervention: Instruction leaflets (CG)
Number of subjects: 54
Study 26183659 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based program (n=32)
Number of subjects: 65
Study 26183659 — intervention group
Group type: COMPARATOR
Intervention: Usual self-care (n=33)
Number of subjects: 65
Study 24103472 — intervention group
Group type: EXPERIMENTAL
Intervention: Go4it intervention (7 sessions with an interval of 2 weeks)
Number of subjects: 122
Study 24103472 — intervention group
Group type: COMPARATOR
Intervention: Current regular care (control group)
Number of subjects: 122
Study 21237227 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alfa‐2b (1.5μg/kg/wk) for 24 weeks + weight‐based ribavirin (800‐1200mg/d)
Number of subjects: 682
Study 21237227 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alfa‐2b (1.0μg/kg/wk) for 24 weeks + weight‐based ribavirin (800‐1200mg/d)
Number of subjects: 682
Study 21237227 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alfa‐2b (1.5μg/kg/wk) for 16 weeks + weight‐based ribavirin (800‐1200mg/d)
Number of subjects: 682
Study 21237227 — intervention group
Group type: EXPERIMENTAL
Intervention: Undetectable HCV RNA at week 4
Number of subjects: 682
Study 18946661 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 128
Study 18946661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 17372174 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral deferiprone 75 mg/kg per day (combined group)
Number of subjects: 65
Study 17372174 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous deferoxamine (deferoxamine group)
Number of subjects: 65
Study 15193576 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief computer-mediated intervention (30-minute session)
Number of subjects: 205
Study 15193576 — intervention group
Group type: COMPARATOR
Intervention: Control (regular programs without intervention)
Number of subjects: 205
Study 11575053 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐help materials delivered by a physician with advice to change diet
Number of subjects: 2111
Study 9709942 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg/day DHT gel
Number of subjects: 25
Study 9709942 — intervention group
Group type: EXPERIMENTAL
Intervention: 32 mg/day DHT gel
Number of subjects: 25
Study 9709942 — intervention group
Group type: EXPERIMENTAL
Intervention: 64 mg/day DHT gel
Number of subjects: 25
Study 7930274 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed dose subcutaneous heparin (12,500 U every 12 h delayed until 4 h after the end of streptokinase therapy)
Number of subjects: 28
Study 3259071 — intervention group
Group type: EXPERIMENTAL
Intervention: Various treatments
Number of subjects: 52
Study 3259071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 29243341 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% carteolol hydrochloride drops administered to the lesion surface twice daily for 6 months
Number of subjects: 349
Study 29243341 — intervention group
Group type: COMPARATOR
Intervention: Observation (no treatment)
Number of subjects: 349
Study 27306192 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone augmentation
Number of subjects: 138
Study 27306192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 23574695 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviourally plus culturally tailored (BCT) information
Number of subjects: 623
Study 23574695 — intervention group
Group type: COMPARATOR
Intervention: Behaviourally tailored (BT) information
Number of subjects: 623
Study 23574695 — intervention group
Group type: COMPARATOR
Intervention: Generic information (GI)
Number of subjects: 623
Study 23890460 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy massage
Number of subjects: 115
Study 23890460 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexology
Number of subjects: 115
Study 20923712 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin (10 mL)
Number of subjects: 33
Study 20923712 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin (30 mL)
Number of subjects: 33
Study 20923712 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 33
Study 17953718 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat 40 mg
Number of subjects: 68
Study 17953718 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat 80 mg (multiple dosing)
Number of subjects: 68
Study 17953718 — intervention group
Group type: COMPARATOR
Intervention: Febuxostat 80 mg (single dosing)
Number of subjects: 68
Study 17953718 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat 120 mg (single dosing)
Number of subjects: 68
Study 17953718 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat 80 mg (single dosing with antacid)
Number of subjects: 68
Study 16586149 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine (0.35 mg hydroxytyrosol)
Number of subjects: 0
Study 16586149 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (1.7 mg hydroxytyrosol)
Number of subjects: 0
Study 14613272 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg/day
Number of subjects: 475
Study 14613272 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg/day
Number of subjects: 475
Study 14613272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 475
Study 10743881 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of power motivation and strong power-sex associations in men
Number of subjects: 0
Study 10743881 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of affiliation-intimacy motivation in women
Number of subjects: 0
Study 10743881 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong power-sex associations in women with high affiliation-intimacy motivation
Number of subjects: 0
Study 10743881 — intervention group
Group type: COMPARATOR
Intervention: Weak power-sex associations in men
Number of subjects: 0
Study 8697551 — intervention group
Group type: EXPERIMENTAL
Intervention: TOF-DI
Number of subjects: 60
Study 8697551 — intervention group
Group type: EXPERIMENTAL
Intervention: PTT-DI
Number of subjects: 60
Study 1396254 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin therapy
Number of subjects: 110
Study 1396254 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical closure of the ductus arteriosus
Number of subjects: 110
Study 1396254 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin therapy (presymptomatic treatment)
Number of subjects: 110
Study 1396254 — intervention group
Group type: EXPERIMENTAL
Intervention: Ductus arteriosus size at 3 days (ultrasound study)
Number of subjects: 110
Study 1396254 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to large ductus arteriosus at 3 days
Number of subjects: 110
Study 3906673 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen (25 to 60 mg per day)
Number of subjects: 13
Study 3906673 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (10 to 40 mg per day)
Number of subjects: 13
Study 3906673 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen (long-term study)
Number of subjects: 13
Study 30710885 — intervention group
Group type: EXPERIMENTAL
Intervention: ω-3 supplementation
Number of subjects: 68
Study 30710885 — intervention group
Group type: COMPARATOR
Intervention: Standard formula without ω-3 (control group)
Number of subjects: 68
Study 29351167 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine intake
Number of subjects: 14
Study 29351167 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 27442674 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 μg/kg loading before anesthesia induction and 0.3 μg/kg/h infusion during surgery)
Number of subjects: 60
Study 27442674 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 60
Study 24637890 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgery
Number of subjects: 379
Study 24637890 — intervention group
Group type: COMPARATOR
Intervention: Prolonged conservative care
Number of subjects: 379
Study 24637890 — intervention group
Group type: EXPERIMENTAL
Intervention: Disabling back pain
Number of subjects: 379
Study 24637890 — intervention group
Group type: EXPERIMENTAL
Intervention: Disabling back pain without nerve root compression
Number of subjects: 379
Study 22240172 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day mifepristone-misoprostol interval
Number of subjects: 227
Study 22240172 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-day mifepristone-misoprostol interval
Number of subjects: 227
Study 22240172 — intervention group
Group type: EXPERIMENTAL
Intervention: History of curettage
Number of subjects: 227
Study 22240172 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal indications for TOP
Number of subjects: 227